Drugs / hUC-MSC-sEV-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07232563 | Dec 2025 → Jun 2027 expected | ischemic stroke | Zhujiang Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06607900 | Jul 2025 → Aug 2027 expected | Alzheimer disease, Lewy body dementia, Parkinson disease, amyotrophic lateral sclerosis +2 | Xuanwu Hospital, Beijing | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hUC-MSC-SEV-001 | “Experimental drug: hUC-MSC-SEV-001 nasal drops derived from small extracellular vesicles of human umbilical cord mesenchymal stem cells” NCT07232563 ↗ |
| Modality | Other / unclassified | “human umbilical cord mesenchymal stem cell-derived small extracellular vesicles hUC-MSC-sEV-001 nasal drops” NCT06607900 ↗ |
| Route | Intranasal | “hUC-MSC-sEV-001 nasal drops” NCT06607900 ↗ |